Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

1. Delayed Radiation Recall in Patients Receiving Cabozantinib: A Case Report and Review of the Literature.Advances in radiation oncology · 2024
   Article
2. Clinical considerations on monkeypox antiviral medications: An overview.Pharmacology research & perspectives · 2024
   Review
3. Cabozantinib inhibits tumor growth in mice with ovarian cancer.American journal of cancer research · 2024
   Article
4. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.Journal for immunotherapy of cancer · 2022
   Review
5. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.JAMA network open · 2022
   Article
6. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.Clinical genitourinary cancer · 2022
   Article
7. Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning.Oncotarget · 2022
   Article
8. All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma.Journal of bone oncology · 2021
   Review
9. Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks.RSC medicinal chemistry · 2021
   Article
10. TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment?Expert opinion on therapeutic targets · 2021
    Review
11. First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis.Therapeutic advances in medical oncology · 2020
    Article
12. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer.Frontiers in oncology · 2020
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract